Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Fujiwara

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Journal of Alzheimer'S Disease : JAD|April 25, 2026
Dementia screening with the Rivermead Behavioural Memory Test: A machine learning analysisYu Fujiwara, Katsutaka Toyoda, Soichiro Maruyama, et al.
Targeted Oncology|November 2, 2025
The Efficacy and Safety of Beta-blockers and Immune Checkpoint Inhibitors in Patients with Cancer: A Systematic Review and Meta-analysisKota Tokunaga, Yu Fujiwara, Reo Omori, et al.
Cancer Immunology, Immunotherapy : CII|April 26, 2022
Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trialsYu Fujiwara, Nobuyuki Horita, Matthew Harrington, et al.
Cancer Cell|January 19, 2021
Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer HospitalYasuyoshi Sato, Yu Fujiwara, Naoki Fukuda, et al.
European Urology Focus|June 14, 2025
Biological and Clinical Insight into the Prevention and Management of Metastatic Renal Cell Carcinoma with a Sarcomatoid ComponentNicholas J Salgia, Yu Fujiwara, Bo Xu, et al.
Targeted Oncology|April 17, 2026
Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-AnalysisYu Fujiwara, Toshiaki Takahashi, Kazuya Tsuchiya, et al.
JAMA Network Open|September 16, 2024
Heterogeneity in Methods of Estimating Kidney Function for Cancer Clinical Trial EligibilityAlexander B Karol, Rodrigo Paredes, Yu Fujiwara, et al.
Cancer Treatment Reviews|September 4, 2022
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapyYu Fujiwara, Shumei Kato, Mary K Nesline, et al.
JNCI Cancer Spectrum|June 3, 2026
Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysisAnneliese Markus, Kazuya Tsuchiya, Toshiaki Takahashi, et al.
Critical Reviews in Oncology/Hematology|April 13, 2024
C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysisYu Fujiwara, Alexander B Karol, Himanshu Joshi, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Journal of Alzheimer'S Disease : JAD|April 25, 2026
Dementia screening with the Rivermead Behavioural Memory Test: A machine learning analysisYu Fujiwara, Katsutaka Toyoda, Soichiro Maruyama, et al.
Targeted Oncology|November 2, 2025
The Efficacy and Safety of Beta-blockers and Immune Checkpoint Inhibitors in Patients with Cancer: A Systematic Review and Meta-analysisKota Tokunaga, Yu Fujiwara, Reo Omori, et al.
Cancer Immunology, Immunotherapy : CII|April 26, 2022
Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trialsYu Fujiwara, Nobuyuki Horita, Matthew Harrington, et al.
Cancer Cell|January 19, 2021
Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer HospitalYasuyoshi Sato, Yu Fujiwara, Naoki Fukuda, et al.
European Urology Focus|June 14, 2025
Biological and Clinical Insight into the Prevention and Management of Metastatic Renal Cell Carcinoma with a Sarcomatoid ComponentNicholas J Salgia, Yu Fujiwara, Bo Xu, et al.
Targeted Oncology|April 17, 2026
Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-AnalysisYu Fujiwara, Toshiaki Takahashi, Kazuya Tsuchiya, et al.
JAMA Network Open|September 16, 2024
Heterogeneity in Methods of Estimating Kidney Function for Cancer Clinical Trial EligibilityAlexander B Karol, Rodrigo Paredes, Yu Fujiwara, et al.
Cancer Treatment Reviews|September 4, 2022
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapyYu Fujiwara, Shumei Kato, Mary K Nesline, et al.
JNCI Cancer Spectrum|June 3, 2026
Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysisAnneliese Markus, Kazuya Tsuchiya, Toshiaki Takahashi, et al.
Critical Reviews in Oncology/Hematology|April 13, 2024
C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysisYu Fujiwara, Alexander B Karol, Himanshu Joshi, et al.
Pageof 7